On June 6, 2025, Nektar Therapeutics (the "Company") filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Increase in Authorized Shares Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock, par value $0.0001 (the "Common Stock"), from 300,000,000 shares to 390,000,000 shares. The Increase in Authorized Shares Amendment was previously approved by the Company's stockholders at the Annual Meeting of Stockholders held on May 23, 2025 and became effective upon its filing.

A copy of the Increase in Authorized Shares Amendment is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Reverse Stock Split Amendment") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's Common Stock at a ratio of one-for-fifteen (the "Reverse Stock Split"). The Reverse Stock Split Amendment provides that the Reverse Stock Split will become effective as of 11:59 p.m. Eastern Time on June 8, 2025 (the "Effective Time"), at which time every fifteen shares of the Company's Common Stock issued and outstanding immediately prior to the Effective Time will be automatically combined into one share of Common Stock. No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, any fractional shares resulting from the Reverse Stock Split will be rounded up at the participant level with The Depository Trust Company, if such shares of Common Stock are held directly or rounded down to the nearest whole share of Common Stock, if such shares are subject to an award granted under the 2017 Amended and Restated Performance Incentive Plan.

Trading of the Company's common stock on a split-adjusted basis will begin at market open on June 9, 2025 under the existing symbol "NKTR" and new CUSIP number 640268306. The Reverse Stock Split will not change the number of authorized shares of the Company's Common Stock, which will remain at 390,000,000 shares following effect of the Increase in Authorized Shares Amendment.

A copy of the Reverse Stock Split Amendment is filed as Exhibit 3.2 hereto and is incorporated herein by reference.